SRD5A2 and benign prostatic hyperplasia: We found that PPE inhibits human SRD5A2 promoter activity and attenuates testosterone-induced prostatic hypertrophy and pathological changes in prostate tissue by reducing the expression of SRD5A2 as well as serum DHT levels, and the results were comparable to those in the finasteride-treated group used as a positive control.